Blogger's Note: this abstract does not indicate if Lynch Syndrome patients were included; of interest, especially, in light of the scarcity of research specific to UTUC (of the ureter/renal pelvis)
abstract
Trabectedin plus pegylated liposomal doxorubicin: the return of a treatment option for ovarian cancer
John Clare
Future Oncology, December 2013, Vol. 9, No. 12s, Pages 1-1.
Citation | Full Text | PDF (197 KB) | PDF Plus(198 KB)
|
Reprints & Permissions
|
Introduction: 1 year of silence?
Andrés Poveda, Eric Pujade-Lauraine
Future Oncology, December 2013, Vol. 9, No. 12s, Pages 3-3.
Citation | Full Text | PDF (221 KB) | PDF Plus(222 KB)
|
Reprints & Permissions
|
Trabectedin mechanism of action: what’s new?
Maurizio D’Incalci
Future Oncology, December 2013, Vol. 9, No. 12s, Pages 5-10.
Summary | Full Text | PDF (1476 KB) | PDF Plus(1477 KB)
|
Reprints & Permissions
|
Biology of ovarian cancer and trabectedin mechanism of action
Isabelle Ray-Coquard
Future Oncology, December 2013, Vol. 9, No. 12s, Pages 11-17.
Summary | Full Text | PDF (1472 KB) | PDF Plus(1473 KB)
|
Reprints & Permissions
|
Optimizing treatment of the partially platinum-sensitive ovarian cancer patient
Nicoletta Colombo
Future Oncology, December 2013, Vol. 9, No. 12s, Pages 19-23.
Summary | Full Text | PDF (493 KB) | PDF Plus(494 KB)
|
Reprints & Permissions
|
Discussion: session 1
Jalid Sehouli, Josep M del Campo, Domenica Lorusso
Future Oncology, December 2013, Vol. 9, No. 12s, Pages 25-27.
Citation | Full Text | PDF (367 KB) | PDF Plus(367 KB)
|
Reprints & Permissions
|
Increasing the chances for platinum-sensitive ovarian cancer patients
Antonio González
Future Oncology, December 2013, Vol. 9, No. 12s, Pages 29-35.
Summary | Full Text | PDF (946 KB) | PDF Plus(947 KB)
|
Reprints & Permissions
|